Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

JW (Cayman) Therapeutics Co. Ltd
藥明巨諾（開曼）有限公司*
(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 2126)

VOLUNTARY ANNOUNCEMENT
RESEARCH AND DEVELOPMENT UPDATE
PRESENTATION OF JWCAR201 IIT STUDY DATA AT THE 67TH AMERICAN SOCIETY OF HEMATOLOGY ANNUAL MEETING

JW (Cayman) Therapeutics Co. Ltd (the "**Company**" or "**JW Therapeutics**", together with its subsidiaries, the "**Group**"), an independent and innovative biotechnology company focusing on developing, manufacturing and commercializing cell immunotherapy products, announced that the Company presented IIT study data for JWCAR201 at the 67th American Society of Hematology Annual Meeting.

About JWCAR201

JWCAR201 is an autologous CAR-T product developed by JW Therapeutics that targets CD19/CD20.

JWCAR201 IIT Study Data Summary

This updated data comes from a single-arm, open-label, multicenter, dose-exploration IIT study conducted in China. The starting dose was set at 25×10^6 CAR+ T cells. A two-stage CRM-designed dose-exploration protocol was used to evaluate the safety and preliminary efficacy of JWCAR201 in patients with relapsed/refractory (r/r) diffuse large B-cell lymphoma (DLBCL) at three dose levels: 25×10^6 CAR+ T cells, 50×10^6 CAR+ T cells, and 100×10^6 CAR+ T cells.

As of October 30, 2025, seven enrolled subjects in this study have completed JWCAR201 infusion, and preliminary safety, efficacy, and pharmacokinetic/pharmacodynamic (PK/PD) studies have been completed across the three dose groups.

The seven patients who underwent infusion in this study had a median age of 56 years (range: 42–72 years) and 42.9% were male. Those patients have significantly high-risk characteristics: 85.7% had DLBCL-Not Otherwise Specified (NOS), 57.1% had non-Germinal Center B-cell-like (GCB) subtypes, 57.1% had an International Prognostic Index (IPI) score ≥3, 71.4% had double-expression lymphoma (MYC/BCL2), 28.6% had bulky lesions (≥7 cm), and 42.9% had abnormal P53 levels. Furthermore, 42.9% of patients had received ≥3 lines of prior therapy, 71.4% were primary refractory, and 85.7% were resistant to their most recent treatment regimen. All patients had received multiple treatments prior to this study but still experienced disease progression, highlighting the urgent need for new and effective treatments.

As of October 30, 2025, preliminary results from this study showed that the best overall response rate (ORR) reached 100% (7/7) and the complete response rate (CRR) reached 85.7% (6/7) among the seven patients. Except for one patient who withdrew from the study at D90 with partial response (PR), the remaining six patients maintained remission until D180 or longer follow-up. The median duration of response (DOR), progression-free survival (PFS), and overall survival (OS) have not yet been reached, demonstrating significant preliminary efficacy.

Preliminary safety results showed that among the seven patients who received infusions: three patients (42.9%) experienced Grade 1 Cytokine Release Syndrome (CRS); one patient (14.3%) experienced Grade 1 Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS). No high-grade CRS or ICANS occurred, and no dose-limiting toxicities (DLTs) occurred. Other adverse events: all patients experienced treatment-related adverse events, mainly predictable and manageable hematological toxicities, including neutropenia, thrombocytopenia, and anemia, all of which recovered to baseline or completely recovered. The safety results of this study indicate that JWCAR201 treatment for r/r DLBCL is safe and manageable.

This study is still ongoing, in order to accumulate data over a longer follow-up period.

Based on the aforementioned findings, we believe that JWCAR201 demonstrates excellent efficacy, a favorable safety profile with manageable adverse reactions, and exhibits significant potential for rapid advancement to the Investigational New Drug stage. We will continue our efforts to accelerate the development of this innovative therapy.

About Relmacabtagene Autoleucel Injection

Relmacabtagene autoleucel injection (abbreviated as **relma-cel**, trade name for oncology indications: Carteyva®) is an autologous anti-CD19 CAR-T cell immunotherapy product independently developed by JW Therapeutics based on a CAR-T cell process platform of Juno Therapeutics (a Bristol Myers Squibb company). Being the first product of JW Therapeutics, Carteyva® has been approved by the NMPA for three indications, including

the treatment of adult patients with relapsed or refractory large B-cell lymphoma (r/r LBCL) after two or more lines of systemic therapy; the treatment of adult patients with follicular lymphoma that is refractory or that relapses within 24 months of second-line or above systemic treatment (r/r FL), and the treatment of adult patients with relapsed or refractory mantle cell lymphoma (r/r MCL) after second-line or higher systemic therapy including Bruton tyrosine kinase inhibitor (BTKi) treatment making it the first CAR-T product approved as a Category 1 biologics product in China. Currently, it is the only CAR-T product in China that has been simultaneously included in the National Significant New Drug Development Program, priority review and breakthrough therapy designations.

About JW Therapeutics

JW Therapeutics (Stock Code: 2126) is an independent and innovative biotechnology company focusing on developing, manufacturing and commercializing cell immunotherapy products. Since its founding in 2016, JW Therapeutics has built an integrated platform for product development in cell immunotherapy, as well as a product pipeline covering hematologic malignancies, solid tumors and autoimmune diseases. JW Therapeutics is committed to bringing breakthrough and quality cell immunotherapy products and the hope of a cure to patients in China and beyond, and to leading the healthy and standardized development of China's cell immunotherapy industry. For more information, please visit **www.jwtherapeutics.com**.

Cautionary Statement required by Rule 18A.05 of the Rules Governing the Listing of Securities of The Stock Exchange of Hong Kong Limited: JW Therapeutics cannot guarantee that it will be able to develop, or ultimately market relma-cel or Carteyva® successfully. Shareholders and potential investors of JW Therapeutics are advised to exercise due care when dealing in the shares of JW Therapeutics.

By order of the Board
JW (Cayman) Therapeutics Co. Ltd
藥明巨諾（開曼）有限公司*
Min Liu
Chairman

Shanghai, PRC, December 8, 2025

As at the date of this announcement, the Board of Directors of the Company comprises Mr. Min Liu as Chairman and executive Director, Dr. Yiping James Li, Ms. Xing Gao, Dr. Sungwon Song and Dr. Cheng Liu as non-executive Directors, and Mr. Kin Cheong Kelvin Ho, Dr. Debra Yu and Mr. Peng Kuan Chan as independent non-executive Directors.

* *For identification purpose only*